The BTF3 (Basic Transcription Factor 3) antibody targets a protein component of the NC2 (Negative Cofactor 2) complex, which plays a dual role in transcriptional regulation. BTF3. also known as NC2β, forms a heterodimer with NC2α to modulate RNA polymerase II-mediated transcription. It represses basal transcription by binding to TATA-box-binding protein (TBP) and blocking preinitiation complex assembly, while also enhancing activated transcription in certain contexts. BTF3 is ubiquitously expressed and evolutionarily conserved, underscoring its fundamental role in cellular processes. Studies link BTF3 to cell cycle progression, apoptosis, and differentiation, with dysregulation observed in cancers such as neuroblastoma and breast cancer. Antibodies against BTF3 are widely used in research to investigate its expression patterns, subcellular localization, and interaction partners via techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation. These tools have helped elucidate BTF3's involvement in oncogenic pathways and its potential as a diagnostic or prognostic biomarker. Recent work also explores its role in developmental biology and response to DNA damage. Commercial BTF3 antibodies are typically raised in rabbits or mice, validated for specificity across human and model organisms.